GeoVax Labs (NASDAQ:GOVX) Releases Quarterly Earnings Results, Beats Estimates By $0.38 EPS

GeoVax Labs (NASDAQ:GOVX) posted its quarterly earnings results on Tuesday. The company reported ($0.91) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.38, Zacks reports. The company had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same quarter in the prior year, the firm earned ($4.80) EPS.

GeoVax Labs Trading Down 13.8 %

Shares of NASDAQ GOVX traded down $0.45 on Wednesday, reaching $2.80. 2,612,033 shares of the company traded hands, compared to its average volume of 2,525,411. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $11.18. The company has a 50 day moving average of $2.44 and a 200 day moving average of $2.59.

Analyst Ratings Changes

Several analysts recently issued reports on GOVX shares. EF Hutton Acquisition Co. I upgraded shares of GeoVax Labs to a “strong-buy” rating in a report on Tuesday, July 23rd. Noble Financial boosted their price objective on shares of GeoVax Labs from $6.00 to $10.00 and gave the company an “outperform” rating in a report on Monday, August 19th. Roth Capital raised shares of GeoVax Labs to a “strong-buy” rating in a research report on Tuesday, July 16th. Alliance Global Partners began coverage on shares of GeoVax Labs in a research report on Monday. They set a “buy” rating and a $15.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of GeoVax Labs in a report on Monday, August 12th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, GeoVax Labs currently has a consensus rating of “Buy” and a consensus target price of $13.25.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.